Efocipegtrutide
| Clinical data | |
|---|---|
| Other names | HM15211 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| ChEMBL | |
Efocipegtrutide (HM15211) is a triple agonist of the glucagon, GIP, and glucagon-like peptide 1 receptors. It is being studied for obesity and nonalcoholic steatohepatitis.[1][2][3]
References[edit]
- ^ Kalra, Sanjay; Bhattacharya, Saptarshi; Kapoor, Nitin (August 2021). "Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)". Diabetes Therapy. 12 (8): 2133–2147. doi:10.1007/s13300-021-01113-y. ISSN 1869-6953. PMC 8342688. PMID 34268675.
- ^ Kim, Jung Kuk; Lee, Jong Suk; Park, Eunjin; Lee, Jongsoo; Bae, Sungmin; Kim, Daejin; Choi, In Young (1 June 2020). "1804-P: HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist, Exhibits Anti-inflammatory and Fibrotic Effects in AMLN/TAA–Induced Liver Inflammation and Fibrosis Mice". Diabetes. 69 (Supplement_1). doi:10.2337/db20-1804-P. S2CID 225811407.
- ^ Abdelmalek, Manal F.; Suzuki, Ayako; Sanchez, Willian; Lawitz, Eric; Filozof, Claudia; Cho, Hyungjin; Baek, Eunhye; Choi, JaeDuk; Baek, Seungjae (July 2023). "A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 study". Contemporary Clinical Trials. 130: 107176. doi:10.1016/j.cct.2023.107176. ISSN 1559-2030. PMID 37028504. S2CID 258001100.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |